# To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN060 in ESRD Dialysis Patients

> **NCT07201467** · PHASE1,PHASE2 · RECRUITING · sponsor: **Suzhou Alphamab Co., Ltd.** · enrollment: 12 (estimated)

## Conditions studied

- End-Stage Renal Disease Requiring Haemodialysis

## Interventions

- **DRUG:** KN060

## Key facts

- **NCT ID:** NCT07201467
- **Lead sponsor:** Suzhou Alphamab Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-22
- **Primary completion:** 2027-08-15
- **Final completion:** 2027-12-15
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07201467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07201467, "To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN060 in ESRD Dialysis Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07201467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*